{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:49Z","timestamp":1793830909760,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ygyno.2019.01.025","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T08:46:30Z","timestamp":1549010790000},"page":"376-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"153","author":[{"given":"Stephanie L.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf S.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.01.025_bb0005","series-title":"Survival Rates for Ovarian Cancer, by Stage","author":"Society AC","year":"2018"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2003.06.139","article-title":"Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study","volume":"21","author":"Glehen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0015","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531","article-title":"Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394)","volume":"36","author":"Goere","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0025","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-016-5096-4","article-title":"Evaluation of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin in the Era of Value-Based Medicine","volume":"23","author":"Vanounou","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0030","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","article-title":"Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer","volume":"33","author":"Cowan","year":"2017","journal-title":"Int. J. Hyperthermia"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-015-0329-5","article-title":"The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer","volume":"16","author":"van Driel","year":"2015","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0055","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2007.13.1961","article-title":"Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Havrilesky","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2014.10.020","article-title":"A cost-utility analysis of NRG Oncology\/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer","volume":"136","author":"Cohn","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2014.02.012","article-title":"Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer","volume":"89","author":"Hodges","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.1999.17.1.312","article-title":"Decision analysis as an aid to determining the management of early low rectal cancer for the individual patient","volume":"17","author":"Temple","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0016-5085(91)90081-U","article-title":"Quality of life of patients with ulcerative colitis preoperatively and postoperatively","author":"McLeod","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0080","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037813","article-title":"Peristomal Skin Complications Are Common, Expensive, and Difficult to Manage: A Population Based Cost Modeling Study","volume":"7","author":"Meisner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0972-9941.181329","article-title":"Reversal of the Hartmann's procedure: A comparative study of laparoscopic versus open surgery","volume":"13","author":"Melkonian","year":"2017","journal-title":"J Minim Access Surg"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0095","series-title":"Tom\u2019s Inflation Calculator","year":"2018"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2018.07.019","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer","volume":"151","author":"Behbakht","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0105","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1002\/cncr.28283","article-title":"Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer","volume":"119","author":"Barnett","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0110","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e3181c9b53c","article-title":"Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program","volume":"251","author":"Chua","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0120","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1245\/s10434-018-6508-4","article-title":"Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis","volume":"25","author":"Lee","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0125","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0130","series-title":"CMS Physician Fee Schedule Search","year":"2017"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0135","series-title":"Physician and Other Supplier Data CY 2015","author":"Services CfMaM","year":"2015"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0140","series-title":"Physician and Other Supplier Public Use File (POSPUF)","author":"Medicaid CfMa","year":"2015"},{"key":"10.1016\/j.ygyno.2019.01.025_bb0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2011.09.028","article-title":"An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer","volume":"124","author":"Dalton","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2017.02.014","article-title":"Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.025_bb0155","unstructured":"Salary for Cardio-Pulmonary Perfusionist in the United States."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819300678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819300678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:43:56Z","timestamp":1758771836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819300678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0090825819300678"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}